A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer

Marinis, Filippo de; Atmaca, Akin; Tiseo, Marcello; Giuffreda, Libero; Rossi, Antonio; Gebbia, Vittorio; Antonio, Chiara D’; Zotto, Laura Dal; Al‐Batran, Salah‐Eddin; Marsoni, Silvia; Wolf, M.

doi:10.1097/jto.0b013e318293d88c

Cited by 47 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical phase II trial in pre-treated SCLC patients using panobinostat, a multi-HDAC inhibitor, was prematurely terminated due to lack of activity. However, de Marinis and colleagues stated at least a moderate activity of panobinostat when applied to SCLC patients because 2 of 19 patients showed a partial response (24). Hence, other Notch re-activation mechanisms might be advantageous in treating SCLC.…”

Section: Targeting Notch Signaling In Sclcmentioning

confidence: 99%

Notch signaling triggers the tumor heterogeneity of small cell lung cancer

2017

View full text Add to dashboard Cite

Section: Targeting Notch Signaling In Sclcmentioning

confidence: 99%

Notch signaling triggers the tumor heterogeneity of small cell lung cancer

2017

View full text Add to dashboard Cite

“…Several noncomparative, phase II studies (n = 7-47) of single-agent [50][51][52][53] or combination treatment [54, 55] with oral [50,[52][53][54][55] or intravenous [51] panobinostat in solid tumours (previously treated, extensive-or limitedstage small-cell lung cancer [50], previously treated, castration-resistant prostate cancer [51], previously gemcitabine-treated, progressing, advanced pancreatic cancer [54], refractory metastatic renal cell carcinoma [52], advanced, pretreated soft-tissue sarcoma [53], and recurrent glioblastoma [55]) indicate that it is unlikely to be effective in these indications.…”

Section: Solid Tumoursmentioning

confidence: 99%

Panobinostat: First Global Approval

Garnock-Jones

2015

Drugs

169

116

View full text Add to dashboard Cite

Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent valid targets in the search for cancer therapeutics. Oral panobinostat is approved in the US, as combination therapy with bortezomib and dexamethasone in patients with recurrent multiple myeloma who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory agent. Regulatory submissions have been made for the use of combination therapy with panobinostat in patients with recurrent multiple myeloma in the EU and Japan. Panobinostat is in various stages of clinical development worldwide for a range of haematological and solid tumours. This article summarizes the milestones in the development of panobinostat leading to this first approval for multiple myeloma.

show abstract

“…1 and Table 1). The included studies examining the different HDACi were divided as follows: 22 studies for Romidepsin , 14 for Panobinostat [33][34][35][36][37][38][39][40][41][42][43][44][45][46], 14 for Vorinostat [47][48][49][50][51][52][53][54][55][56][57][58][59][60], 7 for Belinostat [61][62][63][64][65][66][67], 4 for Valproate [68][69][70][71] and 1 for Entinostat [6]. A total of 3268 patients were identified from 62 studies, and were subsequently divided into six HDACi specific groups for subgroup analyses.…”

Section: Resultsmentioning

confidence: 99%